JP2016538545A - 肝臓癌の診断及び予後判定のための材料及び方法 - Google Patents

肝臓癌の診断及び予後判定のための材料及び方法 Download PDF

Info

Publication number
JP2016538545A
JP2016538545A JP2016530873A JP2016530873A JP2016538545A JP 2016538545 A JP2016538545 A JP 2016538545A JP 2016530873 A JP2016530873 A JP 2016530873A JP 2016530873 A JP2016530873 A JP 2016530873A JP 2016538545 A JP2016538545 A JP 2016538545A
Authority
JP
Japan
Prior art keywords
liver
protein
cell
marker
marker proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016530873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538545A5 (OSRAM
Inventor
アンドリュー ワード マルコルム
アンドリュー ワード マルコルム
ヒューゴ ピケ イアン
ヒューゴ ピケ イアン
ジェームス ブリットン デビッド
ジェームス ブリットン デビッド
ミトラ ビクラム
ミトラ ビクラム
デビッド ヒートン ニゲル
デビッド ヒートン ニゲル
ゼン ヨー
ゼン ヨー
クアグリア アルベルト
クアグリア アルベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Original Assignee
Electrophoretics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd filed Critical Electrophoretics Ltd
Publication of JP2016538545A publication Critical patent/JP2016538545A/ja
Publication of JP2016538545A5 publication Critical patent/JP2016538545A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2016530873A 2013-11-13 2014-11-13 肝臓癌の診断及び予後判定のための材料及び方法 Pending JP2016538545A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1320061.3 2013-11-13
GBGB1320061.3A GB201320061D0 (en) 2013-11-13 2013-11-13 Materials nad methods for diagnosis and prognosis of liver cancer
PCT/GB2014/053368 WO2015071669A2 (en) 2013-11-13 2014-11-13 Materials and methods for diagnosis and prognosis of liver cancer

Publications (2)

Publication Number Publication Date
JP2016538545A true JP2016538545A (ja) 2016-12-08
JP2016538545A5 JP2016538545A5 (OSRAM) 2018-04-12

Family

ID=49818578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016530873A Pending JP2016538545A (ja) 2013-11-13 2014-11-13 肝臓癌の診断及び予後判定のための材料及び方法

Country Status (6)

Country Link
US (1) US20160320395A1 (OSRAM)
EP (1) EP3069142A2 (OSRAM)
JP (1) JP2016538545A (OSRAM)
CA (1) CA2928510A1 (OSRAM)
GB (1) GB201320061D0 (OSRAM)
WO (1) WO2015071669A2 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019537108A (ja) * 2016-10-05 2019-12-19 ユーイーエー エンタープライジズ リミテッド 癌の分類および予後
JP2021173529A (ja) * 2020-04-17 2021-11-01 合同会社Ｈ．Ｕ．グループ中央研究所 胆管がんのバイオマーカー

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105288659B (zh) * 2015-06-01 2019-07-26 北京泱深生物信息技术有限公司 Tenm1基因及其表达产物在诊治乳头状腺癌的应用
KR101750411B1 (ko) * 2015-07-10 2017-06-27 한국생명공학연구원 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
FR3048780B1 (fr) * 2016-03-11 2020-11-06 Commissariat Energie Atomique Procede de diagnostic in vitro d'atteintes hepatiques
WO2017121974A1 (fr) * 2016-01-15 2017-07-20 Commissariat A L'energie Atomique Et Aux Energies Alternatives Procédé de diagnostic in vitro d'atteintes hépatiques
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
SG11201906735RA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
CN115266962B (zh) * 2017-03-31 2024-05-31 北京谷海天目生物医学科技有限公司 蛋白标志物在制备弥漫型胃癌分子分型的产品中的应用及弥漫型胃癌分子分型的分类器
RU2019135845A (ru) 2017-04-11 2021-05-11 Ридженерон Фармасьютикалз, Инк. Анализы для скрининга активности модуляторов членов семейства (17-бета)гидроксистероиддегидрогеназ (hsd17b)
WO2018189215A1 (en) * 2017-04-12 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from hepatocellular carcinoma
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
CN109596829A (zh) * 2017-12-07 2019-04-09 南京医科大学 一种肝癌标志蛋白及其检测方法
WO2019115679A1 (en) * 2017-12-13 2019-06-20 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol A signature to assess prognosis and therapeutic regimen in liver cancer
US12359201B2 (en) 2018-03-21 2025-07-15 Regeneron Pharmaceuticals, Inc. 17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
EP3976195A4 (en) * 2019-05-28 2023-10-18 The Regents Of The University Of California METHODS OF TREATMENT OF SMALL CELL NEUROENDOCRINAL CANCERS AND ASSOCIATED CANCERS
MX2022009517A (es) * 2020-02-10 2022-09-02 Somalogic Operating Co Inc Biomarcadores de esteatohepatitis no alcoholica (nash) y usos de los mismos.
EP4115181A1 (en) * 2020-03-02 2023-01-11 Université de Strasbourg Method for diagnosis and/or prognosis of liver disease progression and risk of hepatocellular carcinoma and discovery of therapeutic compounds and targets to treat liver disease and cancer
CN111748623B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 肝癌患者是否复发的预测标志物及试剂盒
CN111748624B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 用于预测肝癌是否复发的生物标志物
CN112961916B (zh) * 2020-11-10 2024-03-12 上海市肿瘤研究所 Akr1c3作为肝癌预后的生物学标志物及其应用
CN112908470B (zh) * 2021-02-08 2023-10-03 深圳市人民医院 一种基于rna结合蛋白基因的肝细胞癌预后评分系统及其应用
CN113462777A (zh) * 2021-06-28 2021-10-01 武汉大学 P4hb在制备肝细胞癌早期诊断试剂盒及制备或筛选抗肝癌药物中的应用
CN114814001B (zh) * 2022-03-31 2023-02-21 武汉大学 用于制备肝癌检测试剂的新型代谢标志物及其应用
CN115754290A (zh) * 2022-09-26 2023-03-07 浙江大学 一种用于检测早期肝癌的试剂盒
CN115807089B (zh) * 2022-11-14 2024-09-13 石河子大学 肝细胞肝癌预后生物标志物及应用
CN116338189B (zh) * 2023-01-16 2025-08-22 浙江大学医学院附属第一医院 具有蛋白激酶功能的肿瘤标志物ckb在制备肿瘤诊断产品中的应用
CN116386715A (zh) * 2023-03-09 2023-07-04 福建医科大学孟超肝胆医院 用于原发性肝细胞癌蛋白质组分子分型诊断的特征蛋白及其应用
CN117607438A (zh) * 2023-11-23 2024-02-27 浙江大学 一种肝细胞癌鉴别诊断和分化程度检测方法
CN119314683B (zh) * 2024-12-17 2025-02-25 吉林大学第一医院 一种用于肝移植术后预测系统

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522623A (ja) * 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
JP2008522624A (ja) * 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘミアスタリン（ｈｅｍｉａｓｔｅｒｌｉｎ）アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
WO2009113495A1 (ja) * 2008-03-12 2009-09-17 財団法人ヒューマンサイエンス振興財団 肝癌特異的発現遺伝子による肝癌の検査方法並びに肝癌の治療及び予防剤
WO2011078311A1 (ja) * 2009-12-25 2011-06-30 大鵬薬品工業株式会社 肝細胞癌治療のための抗腫瘍剤又は術後補助化学療法剤
WO2013033609A2 (en) * 2011-08-31 2013-03-07 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
DE69128350T2 (de) 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO2003016861A2 (en) 2001-08-14 2003-02-27 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
US20080161203A1 (en) * 2006-12-27 2008-07-03 Su Chun-Lin Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522623A (ja) * 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
JP2008522624A (ja) * 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘミアスタリン（ｈｅｍｉａｓｔｅｒｌｉｎ）アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
WO2009113495A1 (ja) * 2008-03-12 2009-09-17 財団法人ヒューマンサイエンス振興財団 肝癌特異的発現遺伝子による肝癌の検査方法並びに肝癌の治療及び予防剤
WO2011078311A1 (ja) * 2009-12-25 2011-06-30 大鵬薬品工業株式会社 肝細胞癌治療のための抗腫瘍剤又は術後補助化学療法剤
WO2013033609A2 (en) * 2011-08-31 2013-03-07 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019537108A (ja) * 2016-10-05 2019-12-19 ユーイーエー エンタープライジズ リミテッド 癌の分類および予後
JP2023003422A (ja) * 2016-10-05 2023-01-11 ユーイーエー エンタープライジズ リミテッド 癌の分類および予後
JP7539443B2 (ja) 2016-10-05 2024-08-23 ユーイーエー エンタープライジズ リミテッド 癌の分類および予後
JP2021173529A (ja) * 2020-04-17 2021-11-01 合同会社Ｈ．Ｕ．グループ中央研究所 胆管がんのバイオマーカー
JP7471898B2 (ja) 2020-04-17 2024-04-22 合同会社Ｈ．Ｕ．グループ中央研究所 胆管がんのバイオマーカー

Also Published As

Publication number Publication date
EP3069142A2 (en) 2016-09-21
US20160320395A1 (en) 2016-11-03
CA2928510A1 (en) 2015-05-21
WO2015071669A2 (en) 2015-05-21
GB201320061D0 (en) 2013-12-25
WO2015071669A3 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
JP2016538545A (ja) 肝臓癌の診断及び予後判定のための材料及び方法
JP6759229B2 (ja) 前立腺癌の診断および処置におけるフィラミンａを含むマーカーの使用
US10345309B2 (en) Biomarkers for gastric cancer and uses thereof
JP6786499B2 (ja) 膵癌のバイオマーカー
Zhou et al. Overexpression of PrPc, combined with MGr1‐Ag/37LRP, is predictive of poor prognosis in gastric cancer
WO2021076036A1 (en) Apparatuses and methods for detection of pancreatic cancer
KR101690249B1 (ko) 암의 진단 방법 및 암 환자의 전반적 생존 및 무질병 생존의 측정 방법
US20200249235A1 (en) Methods for diagnosing pancreatic cancer
JP6857185B2 (ja) 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法
JP2008527351A (ja) 前立腺癌のバイオマーカーとしてのアポリポタンパク質ａ−ｉｉアイソフォーム
JP2018535433A (ja) デンスブレストを有する女性における乳癌の検出のためのバイオマーカー
KR102000387B1 (ko) 췌관내유두상점액종양의 악성도를 감별할 수 있는 단백질 바이오마커 및 그 용도
Sanchez-Carbayo Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens
WO2012139051A2 (en) Autoantibody biomarkers for iga nephropathy
WO2019115679A1 (en) A signature to assess prognosis and therapeutic regimen in liver cancer
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
Evans et al. Prostate cancer proteomics: the urgent need for clinically validated biomarkers
US20240402177A1 (en) Protein markers for estrogen receptor (er)-positive luminal a (la)-like and luminal b1 (lb1)-like breast cancer
CN111208304B (zh) 肿瘤来源IgG在甲状旁腺癌诊断和预后中的用途
US20250116676A1 (en) Phosphopeptide/phosphoprotein signature predicting basal-like breast cancer recurrence
US20240230651A1 (en) Protein markers for the prognosis of breast cancer progression
Hanash et al. Deciphering the complexity of the cancer proteome for diagnostic applications
US20230059578A1 (en) Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
Sanchez-Carbayo Discovery of cancer biomarkers using antibody arrays
Hussain et al. Proteomic biomarker discovery: review of the science and its challenges with clinical samples.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190604